← Back
Data updated: Jun 28, 2026
WES PHARMA INC
Generics Pharmaceuticals
WES PHARMA INC is a generic drug manufacturer with 4 FDA-approved products.
2017
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
WES PHARMA INC's Key Drugs
WES PHARMA INC's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE — its most strategically important drugs approved in the last 15 years.
WES PHARMA INC's Recent FDA Approvals
New NDA/BLA approvals for WES PHARMA INC over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
WES PHARMA INC's Therapeutic Areas
Disease areas where WES PHARMA INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
WES PHARMA INC Pipeline Snapshot
Active clinical trials for WES PHARMA INC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2017-10-30
- Latest
- 2026-06-18
- Applications
- 5